NGM Biopharmaceuticals Inc (DELISTED) (NGM:DL)
1.54
0.00 (0.00%)
USD |
NASDAQ |
Apr 05, 16:00
NGM Biopharmaceuticals Max Drawdown (5Y): 98.12% for March 31, 2024
Max Drawdown (5Y) Chart
Historical Max Drawdown (5Y) Data
| Date | Value |
|---|---|
| March 31, 2024 | 98.12% |
| February 29, 2024 | 98.12% |
| January 31, 2024 | 98.12% |
| December 31, 2023 | 98.12% |
| November 30, 2023 | 98.12% |
| October 31, 2023 | 97.60% |
| September 30, 2023 | 96.71% |
| August 31, 2023 | 94.08% |
| July 31, 2023 | 92.95% |
| June 30, 2023 | 92.36% |
| May 31, 2023 | 90.68% |
| April 30, 2023 | 89.32% |
| March 31, 2023 | 89.32% |
| February 28, 2023 | 89.32% |
| January 31, 2023 | 89.32% |
| December 31, 2022 | 89.32% |
| November 30, 2022 | 89.32% |
| October 31, 2022 | 89.32% |
| September 30, 2022 | 66.86% |
| August 31, 2022 | 66.86% |
| July 31, 2022 | 66.86% |
| June 30, 2022 | 66.86% |
| May 31, 2022 | 66.86% |
| April 30, 2022 | 60.91% |
| March 31, 2022 | 56.75% |
| Date | Value |
|---|---|
| February 28, 2022 | 55.21% |
| January 31, 2022 | 54.59% |
| December 31, 2021 | 52.83% |
| November 30, 2021 | 52.83% |
| October 31, 2021 | 52.83% |
| September 30, 2021 | 52.83% |
| August 31, 2021 | 52.83% |
| July 31, 2021 | 52.83% |
| June 30, 2021 | 52.83% |
| May 31, 2021 | 52.83% |
| April 30, 2021 | 50.69% |
| March 31, 2021 | 50.69% |
| February 28, 2021 | 50.69% |
| January 31, 2021 | 50.69% |
| December 31, 2020 | 50.69% |
| November 30, 2020 | 50.69% |
| October 31, 2020 | 50.69% |
| September 30, 2020 | 50.69% |
| August 31, 2020 | 50.69% |
| July 31, 2020 | 50.69% |
| June 30, 2020 | 50.69% |
| May 31, 2020 | 50.69% |
| April 30, 2020 | 50.69% |
| March 31, 2020 | 50.69% |
| February 29, 2020 | 45.19% |
Max Drawdown Definition
Max drawdown is an indicator of the risk of a portfolio chosen based on a certain strategy. It measures the largest single drop from peak to bottom in the value of a portfolio before a new peak is achieved.
Max Drawdown (5Y) Range, Past 5 Years
24.34%
Minimum
Jun 2019
98.12%
Maximum
Nov 2023
63.75%
Average
52.83%
Median
May 2021
Max Drawdown (5Y) Benchmarks
| Catalent Inc | 77.62% |
| AIM ImmunoTech Inc | 99.76% |
| Perspective Therapeutics Inc | 91.70% |
| Protalix BioTherapeutics Inc | 94.35% |
| Armata Pharmaceuticals Inc | 99.87% |